1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066–2078.

2. Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol 2010;45:9–16.

3. Atreya R, Neurath MF. IBD pathogenesis in 2014: Molecular pathways controlling barrier function in IBD. Nat Rev Gastroenterol Hepatol 2015;12:67–68.

4. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474:307–317.

5. Gordon H, Burisch J, Ellul P, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis 2024;18:1–37.

6. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1982–1992.

7. Qian XX. Halitosis: an underestimated but important extraintestinal manifestation in inflammatory bowel disease. Intest Res 2024;22:387–388.

8. Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology 2021;161:1118–1132.

9. Na SY, Choi CH, Song EM, et al. Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. Intest Res 2023;21:61–87.

10. Koh SJ, Hong SN, Park SK, et al. Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease. Intest Res 2023;21:43–60.

11. Jeuring SF, van den Heuvel TR, Zeegers MP, et al. Epidemiology and long-term outcome of inflammatory bowel disease diagnosed at elderly age-an increasing distinct entity? Inflamm Bowel Dis 2016;22:1425–1434.

12. Wei H, Zhao Y, Xiang L. Bone health in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2023;17:921–935.

13. Adachi JD, Rostom A. Metabolic bone disease in adults with inflammatory bowel disease. Inflamm Bowel Dis 1999;5:200–211.

14. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn’s disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994;107:1031–1039.

15. Kärnsund S, Lo B, Bendtsen F, Holm J, Burisch J. Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease. World J Gastroenterol 2020;26:5362–5374.

16. Szafors P, Che H, Barnetche T, et al. Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis. Osteoporos Int 2018;29:2389–2397.

17. Ahn HJ, Kim YJ, Lee HS, et al. High risk of fractures within 7 years of diagnosis in asian patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2022;20:e1022–e1039.

18. Lee JM, Han K, Lee KM, Yun JS. Fracture risk in middle-aged and older patients with inflammatory bowel disease: a Korean nationwide population-based cohort study. J Korean Med Sci 2023;38:e275.

19. Ludvigsson JF, Mahl M, Sachs MC, et al. Fracture risk in patients with inflammatory bowel disease: a nationwide population-based cohort study from 1964 to 2014. Am J Gastroenterol 2019;114:291–304.

20. Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem 2010;285:25103–25108.

21. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008;473:139–146.

22. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol 1993;94:174–181.

23. Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011;22:83–89.

24. Blaschke M, Koepp R, Cortis J, et al. IL-6, IL-1β, and TNF-α only in combination influence the osteoporotic phenotype in Crohn’s patients via bone formation and bone resorption. Adv Clin Exp Med 2018;27:45–56.

25. Canalis E. Mechanisms of glucocorticoid action in bone. Curr Osteoporos Rep 2005;3:98–102.

26. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007;18:1319–1328.

27. Tilg H, Moschen AR, Kaser A, Pines A, Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 2008;57:684–694.

28. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777–787.

29. Vernia P, Loizos P, Di Giuseppantonio I, Amore B, Chiappini A, Cannizzaro S. Dietary calcium intake in patients with inflammatory bowel disease. J Crohns Colitis 2014;8:312–317.

30. Ananthakrishnan AN. Vitamin D and inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2016;12:513–515.

31. Nielsen OH, Rejnmark L, Moss AC. Role of vitamin D in the natural history of inflammatory bowel disease. J Crohns Colitis 2018;12:742–752.

32. Bischoff SC, Bager P, Escher J, et al. ESPEN guideline on clinical nutrition in inflammatory bowel disease. Clin Nutr 2023;42:352–379.

33. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol 2017;112:241–258.

34. Buckley L, Guyatt G, Fink HAC, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 2017;69:1521–1537.

35. Ghishan FK, Kiela PR. Vitamins and minerals in inflammatory bowel disease. Gastroenterol Clin North Am 2017;46:797–808.

36. Bertani L, Ribaldone DG, Bellini M, Mumolo MG, Costa F. Inflammatory bowel diseases: is there a role for nutritional suggestions? Nutrients 2021;13:1387.

37. Zhao X, Zhou C, Chen H, et al. Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: a systematic review with network meta-analysis. Medicine (Baltimore) 2017;96:e6378.

38. Lima CA, Lyra AC, Rocha R, Santana GO. Risk factors for osteoporosis in inflammatory bowel disease patients. World J Gastrointest Pathophysiol 2015;6:210–218.

39. van Bodegraven AA, Bravenboer N. Perspective on skeletal health in inflammatory bowel disease. Osteoporos Int 2020;31:637–646.

40. Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 2020;21:300–307e2.

41. Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. J Diabetes Metab Disord 2017;16:21.

42. Neelam PB, Pal R, Gupta P, et al. Sarcopenia is common in ulcerative colitis and correlates with disease activity. Intest Res 2024;22:162–171.

43. Ryan E, McNicholas D, Creavin B, Kelly ME, Walsh T, Beddy D. Sarcopenia and inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2019;25:67–73.

44. Labarthe G, Dolores M, Verdalle-Cazes M, et al. Magnetic resonance imaging assessment of body composition parameters in Crohn’s disease. Dig Liver Dis 2020;52:878–884.

45. Ding NS, Malietzis G, Lung PFC, et al. The body composition profile is associated with response to anti-TNF therapy in Crohn’s disease and may offer an alternative dosing paradigm. Aliment Pharmacol Ther 2017;46:883–891.

46. Bamba S, Inatomi O, Takahashi K, et al. Assessment of body composition from CT images at the level of the third lumbar vertebra in inflammatory bowel disease. Inflamm Bowel Dis 2021;27:1435–1442.

47. Ge X, Jiang L, Yu W, et al. The importance of sarcopenia as a prognostic predictor of the clinical course in acute severe ulcerative colitis patients. Dig Liver Dis 2021;53:965–971.

48. Grillot J, D’Engremont C, Parmentier AL, et al. Sarcopenia and visceral obesity assessed by computed tomography are associated with adverse outcomes in patients with Crohn’s disease. Clin Nutr 2020;39:3024–3030.

49. Galata C, Hodapp J, Weiß C, et al. Skeletal muscle mass index predicts postoperative complications in intestinal surgery for Crohn’s disease. JPEN J Parenter Enteral Nutr 2020;44:714–721.

50. Zhang T, Cao L, Cao T, et al. Prevalence of sarcopenia and its impact on postoperative outcome in patients with Crohn’s disease undergoing bowel resection. JPEN J Parenter Enteral Nutr 2017;41:592–600.

51. Schneider SM, Al-Jaouni R, Filippi J, et al. Sarcopenia is prevalent in patients with Crohn’s disease in clinical remission. Inflamm Bowel Dis 2008;14:1562–1568.

52. Bryant RV, Ooi S, Schultz CG, et al. Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. Aliment Pharmacol Ther 2015;41:895–906.

53. Wallace KL, Zheng LB, Kanazawa Y, Shih DQ. Immunopathology of inflammatory bowel disease. World J Gastroenterol 2014;20:6–21.

54. Thayu M, Denson LA, Shults J, et al. Determinants of changes in linear growth and body composition in incident pediatric Crohn’s disease. Gastroenterology 2010;139:430–438.

55. DiFedele LM, He J, Bonkowski EL, et al. Tumor necrosis factor alpha blockade restores growth hormone signaling in murine colitis. Gastroenterology 2005;128:1278–1291.

56. Nardone OM, de Sire R, Petito V, et al. Inflammatory bowel diseases and sarcopenia: the role of inflammation and gut microbiota in the development of muscle failure. Front Immunol 2021;12:694217.

57. Pandey H, Jain D, Tang DWT, Wong SH, Lal D. Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease. Intest Res 2024;22:15–43.

58. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000;6:583–588.

59. Kai Y, Takahashi I, Ishikawa H, et al. Colitis in mice lacking the common cytokine receptor gamma chain is mediated by IL-6-producing CD4+ T cells. Gastroenterology 2005;128:922–934.

60. Shimizu N, Yoshikawa N, Ito N, et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab 2011;13:170–182.

61. Nishikawa H, Nakamura S, Miyazaki T, et al. Inflammatory bowel disease and sarcopenia: its mechanism and clinical importance. J Clin Med 2021;10:4214.

62. Yoshida T, Delafontaine P. Mechanisms of cachexia in chronic disease states. Am J Med Sci 2015;350:250–256.

63. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:601.

64. Chianca V, Albano D, Messina C, et al. Sarcopenia: imaging assessment and clinical application. Abdom Radiol (NY) 2022;47:3205–3216.

65. Scaldaferri F, Pizzoferrato M, Lopetuso LR, et al. Nutrition and IBD: malnutrition and/or sarcopenia? A practical guide. Gastroenterol Res Pract 2017;2017:8646495.

66. Valentini L, Schaper L, Buning C, et al. Malnutrition and impaired muscle strength in patients with Crohn’s disease and ulcerative colitis in remission. Nutrition 2008;24:694–702.

67. Fatani H, Olaru A, Stevenson R, et al. Systematic review of sarcopenia in inflammatory bowel disease. Clin Nutr 2023;42:1276–1291.

68. Skrzypczak D, Ratajczak AE, Szymczak-Tomczak A, Dobrowolska A, Eder P, Krela-Kaźmierczak I. A vicious cycle of osteosarcopeniain inflammatory bowel diseases-aetiology, clinical implications and therapeutic perspectives. Nutrients 2021;13:293.

69. Kim HK, Suzuki T, Saito K, et al. Effects of exercise and amino acid supplementation on body composition and physical function in community-dwelling elderly Japanese sarcopenic women: a randomized controlled trial. J Am Geriatr Soc 2012;60:16–23.

70. Brook MS, Wilkinson DJ, Phillips BE, et al. Skeletal muscle homeostasis and plasticity in youth and ageing: impact of nutrition and exercise. Acta Physiol (Oxf) 2016;216:15–41.

71. Choi M, Kim H, Bae J. Does the combination of resistance training and a nutritional intervention have a synergic effect on muscle mass, strength, and physical function in older adults? A systematic review and meta-analysis. BMC Geriatr 2021;21:639.

72. Zhao J, Huang Y, Yu X. Effects of nutritional supplement and resistance training for sarcopenia in patients with inflammatory bowel disease: a randomized controlled trial. Medicine (Baltimore) 2022;101:e30386.

73. Zhang T, Ding C, Xie T, et al. Skeletal muscle depletion correlates with disease activity in ulcerative colitis and is reversed after colectomy. Clin Nutr 2017;36:1586–1592.

74. Subramaniam K, Fallon K, Ruut T, et al. Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn’s disease. Aliment Pharmacol Ther 2015;41:419–428.

75. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777–783.

76. Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25–31.

77. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218–1227.

78. Karreman MC, Luime JJ, Hazes JMW, Weel AEAM. The Prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 2017;11:631–642.

79. Vavricka SR, Rogler G, Gantenbein C, et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the swiss inflammatory bowel disease cohort. Inflamm Bowel Dis 2015;21:1794–1800.

80. Zioga N, Kogias D, Lampropoulou V, Kafalis N, Papagoras C. Inflammatory bowel disease-related Spondyloarthritis: the last unexplored territory of rheumatology. Mediterr J Rheumatol 2022;33(Suppl 1):126–136.

81. Asquith M, Sternes PR, Costello ME, et al. HLA alleles associated with risk of ankylosing spondylitis and rheumatoid arthritis influence the gut microbiome. Arthritis Rheumatol 2019;71:1642–1650.

82. Kim YS, Lee J. Musculoskeletal manifestation in inflammatory bowel disease. Korean J Gastroenterol 2019;73:276–284Korean. 83. Hedin CRH, Vavricka SR, Stagg AJ, et al. The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy. J Crohns Colitis 2019;13:541–554.

84. Qaiyum Z, Gracey E, Yao Y, Inman RD. Integrin and transcriptomic profiles identify a distinctive synovial CD8+ T cell subpopulation in spondyloarthritis. Ann Rheum Dis 2019;78:1566–1575.

85. Gracey E, Qaiyum Z, Almaghlouth I, et al. IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis 2016;75:2124–2132.

86. Peeters H, Vander Cruyssen B, Laukens D, et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn’s disease. Ann Rheum Dis 2004;63:1131–1134.

87. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011;140:1704–1712.

88. Seo MR, Yeo J, Park JW, et al. Korean treatment recommendations for patients with axial spondyloarthritis. Korean J Intern Med 2024;39:200.

89. Sheth T, Pitchumoni CS, Das KM. Musculoskeletal manifestations in inflammatory bowel disease: a revisit in search of immunopathophysiological mechanisms. J Clin Gastroenterol 2014;48:308–317.

90. Carubbi F, Alunno A, Viscido A, et al. SpA plus IBD or IBD plus SpA: does commutative property apply? Autoimmun Rev 2023;22:103443.

91. Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs 2012;72:2333–2349.

92. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 2023;82:19–34.

93. Moninuola OO, Milligan W, Lochhead P, et al. Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn’s disease and ulcerative colitis exacerbation. Aliment Pharmacol Ther 2018;47:1428–1439.